Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials.
Saved in:
| Title: | Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials. |
|---|---|
| Authors: | Patel P; Manchester Pharmacy School, Manchester, UK., Howgate E; Manchester Pharmacy School, Manchester, UK., Martin P; AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK., Carlile DJ; AstraZeneca, Early Clinical Development, Innovative Medicines and Early Development Biotech Unit, Da Vinci Building, Royston, Hertfordshire, UK., Aarons L; Manchester Pharmacy School, Manchester, UK., Zhou D; AstraZeneca, Waltham, MA, USA. |
| Source: | British journal of clinical pharmacology [Br J Clin Pharmacol] 2018 Jan; Vol. 84 (1), pp. 52-63. Date of Electronic Publication: 2017 Sep 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2125 |
|---|---|
| DOI: | 10.1111/bcp.13404 |
